Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Arrowhead Pharmaceuticals Seeks Trial Approval for Obesity Drug ARO-ALK7
Latest Hotspot
3 min read
Arrowhead Pharmaceuticals Seeks Trial Approval for Obesity Drug ARO-ALK7
6 December 2024
Arrowhead Pharmaceuticals Seeks Approval to Start Phase 1/2a Trial of ARO-ALK7 for Obesity Treatment.
Read →
Jasper Therapeutics Begins Phase 1b/2a ETESIAN Trial for Briquilimab in Asthma
Latest Hotspot
3 min read
Jasper Therapeutics Begins Phase 1b/2a ETESIAN Trial for Briquilimab in Asthma
6 December 2024
Jasper Therapeutics has reported the initial patient receiving treatment in the Phase 1b/2a ETESIAN trial of Briquilimab for asthma.
Read →
Epsilogen has launched a Phase Ib trial for MOv18 IgE
Latest Hotspot
2 min read
Epsilogen has launched a Phase Ib trial for MOv18 IgE
6 December 2024
Epsilogen has declared the initiation of a Phase Ib trial assessing MOv18 IgE in individuals suffering from platinum-resistant ovarian cancer (PROC).
Read →
FDA Approves OncoC4's IND for AI-081, a Novel PD-1/VEGF Therapy for Solid Tumors
Latest Hotspot
3 min read
FDA Approves OncoC4's IND for AI-081, a Novel PD-1/VEGF Therapy for Solid Tumors
6 December 2024
OncoC4 has received FDA approval for its IND application regarding AI-081, a promising PD-1/VEGF bispecific therapy for advanced solid tumors.
Read →
TORL BioTherapeutics Appoints Aran Maree as CMO and Launches Phase 2 Trial for Ovarian Cancer Treatment
Latest Hotspot
4 min read
TORL BioTherapeutics Appoints Aran Maree as CMO and Launches Phase 2 Trial for Ovarian Cancer Treatment
6 December 2024
TORL BioTherapeutics has named Aran Maree, M.D., as its Chief Medical Officer and has begun a Phase 2 study for TORL-1-23.
Read →
Spyre Therapeutics Begins Phase 1 Trials for New Anti-TL1A Antibodies
Latest Hotspot
4 min read
Spyre Therapeutics Begins Phase 1 Trials for New Anti-TL1A Antibodies
6 December 2024
Spyre Therapeutics Reports First Dosing of Participants in Phase 1 Trials for New Extended Half-Life Anti-TL1A Antibodies.
Read →
FDA Approves Biocon's YESINTEK™ Biosimilar to Stelara®
Latest Hotspot
2 min read
FDA Approves Biocon's YESINTEK™ Biosimilar to Stelara®
6 December 2024
The U.S. FDA has given the green light to Biocon Biologics' biosimilar YESINTEK™, Bmab 1200, which is comparable to J&J's Stelara® (Ustekinumab).
Read →
Distinct Mechanisms and Therapeutic Potential of ASOs and siRNAs in Precision Medicine
Bio Sequence
7 min read
Distinct Mechanisms and Therapeutic Potential of ASOs and siRNAs in Precision Medicine
5 December 2024
In modern gene therapy, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are key nucleic acid drugs that offer new treatment options for genetic and complex diseases.
Read →
Alector Shares AL002 Phase 2 Study Results and Company Updates
Latest Hotspot
4 min read
Alector Shares AL002 Phase 2 Study Results and Company Updates
4 December 2024
Alector reveals findings from the AL002 INVOKE-2 Phase 2 study on early Alzheimer’s disease and shares company updates.
Read →
Revolutionizing Medicine: Advances in siRNA Drugs and Delivery Technologies
Hot Spotlight
8 min read
Revolutionizing Medicine: Advances in siRNA Drugs and Delivery Technologies
4 December 2024
the siRNA therapeutics market is projected to grow substantially from $12.7 billion in 2023 to $39.2 billion by 2029.
Read →
Tenaya Begins Phase 1b Trial of TN-401 for ARRVC Linked to PKP2
Latest Hotspot
4 min read
Tenaya Begins Phase 1b Trial of TN-401 for ARRVC Linked to PKP2
4 December 2024
Tenaya Therapeutics has administered the first dose to a patient in the Phase 1b clinical study of TN-401, part of the RIDGE™-1 trial, aimed at treating ARRVC linked to PKP2.
Read →
European Commission Approves Novartis' Kisqali® for High-Risk HR+/HER2- Early Breast Cancer
Latest Hotspot
4 min read
European Commission Approves Novartis' Kisqali® for High-Risk HR+/HER2- Early Breast Cancer
4 December 2024
Novartis' Kisqali® has secured approval from the European Commission for use in a wide range of patients with HR+/HER2- early breast cancer who are at high risk of recurrence.
Read →